Millennium Management’s VistaGen Therapeutics VTGN Stock Holding History

Millennium Management’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$122K	Buy	+214,000	New	+$130K	﹤0.01%	5308

Other funds holding VTGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

Millennium Management's VTGN Position: Q1 2026 in Review

Millennium Management increased its VistaGen Therapeutics (VTGN) stake by 118% in Q1 2026, buying an estimated $142K and bringing the position to 430,404 shares worth $246K. The position accounts for ﹤0.01% of the portfolio, ranked #5086.

Millennium Management first reported a position in VTGN in Q4 2018 and has held it in 18 quarters since. The position peaked at $2.97M in Q1 2021. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

Millennium Management held 430,404 shares of VistaGen Therapeutics worth $246K as of Q1 2026.
Millennium Management bought 233,359 VistaGen Therapeutics shares in Q1 2026, an estimated $142K.
VistaGen Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #5086 holding.
Millennium Management first reported a position in VistaGen Therapeutics in Q4 2018 and has held it in 18 quarters since.
Millennium Management's VistaGen Therapeutics position peaked at $2.97M in Q1 2021.
56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.